• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Viseon closes $18m Series B

Viseon closes $18m Series B

February 26, 2020 By Sean Whooley

Viseon SpineViseon announced yesterday that it closed a Series B financing round worth $18 million to support a number of company initiatives.

The Irvine, Calif.-based orthopedic spine technology company said it is earmarking the funding for ongoing product development, worldwide regulatory approvals, clinical evaluations, manufacturing scale-up and commercialization efforts. The $18 million round was co-led by Invus Opportunities, affiliates of Wexford Capital and HBM-MedFocus.

Viseon plans to continue building out its proprietary visualization and illumination technologies for minimally invasive spine surgery (MISS) procedures. The single-use, disposable MISS access device is designed for a wide range of cervical, thoracic and lumbar procedures as a replacement for the surgical microscopes and endoscopes that are the standard products used.

In September 2019, the FDA awarded updated clearance for Viseon’s Voyant system for integrating minimally invasive surgical access with high-definition imaging technology. The company closed a $5 million Series A funding round in September 2017 for the MISS technology, having initially won FDA 510(k) clearance for the Voyant system in October 2018.

“We are very pleased to have the ongoing support from our current investment partners, with confidence underscored by inside-only investor participation and oversubscription,” Viseon president & CEO Jeffrey Valko said in a news release. “As fundamental as it may seem, enhanced real-time intraoperative visualization projected onto a large high-definition flat panel display will contribute toward clinical outcomes improvement, procedural efficiency, reduced risk of complications, OR staff involvement teaching opportunity and procedure expansion.”

“We have initiated limited commercial use of Viseon technology and early surgeon response has been very positive,” added Viseon COO Peter Davis. “Viseon continues to strategically expand commercialization working closely with MIS surgeons, collecting additional clinical feedback and utility in the U.S. and we are assessing international commercialization opportunities.”

Filed Under: Business/Financial News, Funding Roundup, Imaging, Orthopedics, Spine, Surgical Tagged With: Viseonspine

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy